If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
125.20    -3.80 (-2.95%)
Bid:
125.60
Ask:
126.80
Spread: 1.20 (0.955%)
Market Cap: £521.35m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Trading Update

29 Jul 2025 07:00

RNS Number : 8873S
James Halstead PLC
29 July 2025
 

 

29 July 2025

 

 

JAMES HALSTEAD PLC (the "Company")

 

Trading Update

James Halstead plc, the commercial flooring manufacturer and international distributor, is providing the following trading update ahead of its results for the year ended 30 June 2025.

 

The Company sells, for the most part, commercial flooring across the world and has seen continued confidence in the segment of resilient sheet flooring but has experienced headwinds against sales of luxury vinyl tile (LVT) principally in Europe, the Company has however successfully managed to grow its market share in the UK. Profit before tax is in line with expectations.

 

Sales in the UK, our largest market, have improved compared to the prior financial year. Having reported that in the prior financial year there was a 5% decline versus the comparative, it is pleasing to note that our performance this year has seen this decline more than fully reverse. This is despite a degree of de-stocking by some customers, particularly those with exposure to the UK domestic carpet market.

 

Sales volumes of LVT have increased, albeit modestly, in a market segment that has seen a large decline in demand. Sales of Polyflor branded LVT products have held up due to their quality and value together with our widely accepted reputation for sustainability and environmental excellence; factors that have helped increase our market share. LVT and sheet vinyl continue to displace carpet sales in the UK market.

 

Notwithstanding this backdrop and solid UK performance, our internal expectations for the UK were higher. An anticipated uplift in demand in the education, healthcare and the prison sectors has not, yet, materialised though sales into the aged care and affordable housing sectors are performing satisfactorily.

 

In Europe, particularly in France and Holland, there has been muted activity in consumer spending which has affected refurbishment demand and new store openings in the retail sector. This has impacted LVT sales and volume declines were further compounded by increased focus of government budgets towards national security, diverting spending away from such areas as construction and social housing.

 

The products we sell are still regarded as market leading but the year has required reacting to a lower level of sales by tight cost control. In this regard, the simple model of holding stock within our distribution chain to supply demand is tried and tested around the globe.

 

In our Rest of World markets, sales have generally been more positive with very good growth, especially in the Americas, the Middle East and Mediterranean regions. Additionally, South Asia has seen the growth of recent years continue and is 38% ahead of the comparative of last year.

 

Notwithstanding the slower sales, the Group's focus on manufacturing efficiency and tight cost control of overheads have protected margins.

 

Operationally, there has been disruption to global trade routes and shipping movements with the uncertainty of tariffs on sales into the USA which has affected deliveries into many markets. However, these uncertainties have been positive regarding the sale of our UK manufactured goods into the USA, as customers seek alternative suppliers to replace products imported from countries where much higher tariffs have been imposed and with continuing uncertainly. This increased demand is despite an additional 10% duty cost to importers of our UK products.

 

In summary, the Company anticipates that sales will be marginally below the 2024 comparative with profit slightly below last year's record levels; although remaining within the range of market expectations. Cash generation alongside reserves continue to underpin an ungeared balance sheet, which remains strong.

 

The Board is confident that the prospects remain solid despite the recent external challenges and side winds.

 

The Company expects to announce its results for the year ended 30 June 2025 towards the end of September 2025.

 

 

 

 

 

Enquiries:

 

James Halstead plc

Tel: 0161 767 2500

Mark Halstead, Executive Chairman

Gordon Oliver, Chief Executive

David Drillingcourt, Finance Director

 

Hudson Sandler

Tel: 020 7796 4133

Nick Lyon / Nick Moore

Panmure Liberum (Nomad and Joint Broker)

Tel: 020 7886 2500

Ed Mansfield / Tom Scrivens

Zeus (Joint Broker)

Ben Thorne / Fraser Marshall

 

Tel: 020 3829 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKFBQCBKDPOB
Date   Source Headline
1st Dec 20174:53 pmRNSResult of AGM
1st Dec 20177:00 amRNSAGM Statement
20th Oct 20173:00 pmRNSAnnual Report & Accounts
2nd Oct 20177:00 amRNSBoard Changes
2nd Oct 20177:00 amRNSPRELIMINARY ANNOUNCEMENT OF AUDITED RESULTS
14th Sep 201712:42 pmRNSNotice of Preliminary Results
14th Sep 20177:00 amRNSNotice of Preliminary Results
1st Aug 201710:43 amRNSTotal Voting Rights
1st Aug 20177:00 amRNSPre-Close Trading Statement
31st Jul 20175:53 pmRNSDirector/PDMR Shareholding
3rd Jul 20175:40 pmRNSTotal Voting Rights
3rd Jul 20175:37 pmRNSBlock listing Interim Review
23rd Jun 20174:12 pmRNSDirector/PDMR Shareholding
12th Jun 201712:54 pmRNSDirector/PDMR Shareholding
9th Jun 20175:37 pmRNSTotal Voting Rights
12th May 20175:29 pmRNSDirector/PDMR Shareholding
12th May 20173:59 pmRNSDirector/PDMR Shareholding
5th Apr 20172:36 pmRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSInterim Results
6th Mar 20177:00 amRNSNotice of Results
30th Jan 20177:00 amRNSPre Close Trading Statement
13th Dec 201611:13 amRNSResult of AGM
2nd Dec 20167:00 amRNSAGM Statement
1st Dec 20167:00 amRNSTotal Voting Rights
1st Nov 201612:24 pmRNSTotal Voting Rights
21st Oct 20167:00 amRNSAnnual Financial Report
3rd Oct 20167:00 amRNSPRELIMINARY ANNOUNCEMENT OF AUDITED RESULTS
21st Sep 20167:00 amRNSNotice of Preliminary Results
15th Aug 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
1st Aug 20167:00 amRNSPre-Close Trading Statement
1st Jul 20163:41 pmRNSBlock listing Interim Review
31st Mar 20167:00 amRNSInterim Results
8th Mar 20167:00 amRNSNotice of Interim Results
1st Feb 20164:51 pmRNSTotal Voting Rights
1st Feb 20167:00 amRNSPre Close Trading Statement
3rd Dec 20155:20 pmRNSDirector/PDMR Shareholding
1st Dec 20152:45 pmRNSTotal Voting Rights
27th Nov 201512:00 pmRNSChairman's Statement to the Annual General Meeting
2nd Nov 201511:39 amRNSTotal Voting Rights
29th Oct 20154:44 pmRNSDirector/PDMR Shareholding
23rd Oct 20159:45 amRNSAnnual Financial Report & Notice of AGM
29th Sep 20157:00 amRNSFinal Results
18th Sep 20157:00 amRNSNotice of Preliminary Results
31st Jul 20157:00 amRNSTotal Voting Rights
29th Jul 20157:00 amRNSPre-Close Trading Statement
28th Jul 20156:00 pmRNSBlocklisting Interim Review
24th Jul 20155:00 pmRNSDirector/PDMR Shareholding
1st Jul 20157:00 amRNSChange of Adviser
3rd Jun 20157:00 amRNSTotal Voting Rights
31st Mar 20157:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.